Clinical trial · Interventional
Imatinib in Adult Patients With Metastatic Ocular Melanoma
A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma
NCT00421317CI-TRIAL-00105473O-Mel-InibterminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study stopped at the end of the first step
Summary
Brief summary (as posted)
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free rate at 3 months
Secondary outcomes (5)
- measure
- Progression-free rate at 6 and 12 months
- measure
- Response rate according to RECIST criteria
- measure
- Toxicity
- measure
- Global survival,Progression-free survival
- measure
- Predictive genomic factors of response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic ocular melanoma * Age \> or = 18 years old * Measurable metastases \> or = 10 mm according to RECIST criteria * PS-WHO \< or = 1 or IK \> 70 percent * Normal hepatic function * PNN \> 1500/mm3, platelets \> or = 100 000/mm3 * Contraception * Informed consent signed Exclusion Criteria: * Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association) * Other evolutive neoplasic disease * Severe hepatic insufficiency * Severe renal insufficiency * Somatic or psychiatric co-morbidity incompatible with the protocol * Leptomeningeal or cerebral metastatic dissemination * Pregnant or lactating woman * Other antitumoral treatment * Patient participating to another clinical trial with an experimental drug * Known hypersensitivity to Imatinib or one of its excipients * Resecable single metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.